22 completed, 4 terminated, 4 unknown, 2 recruiting. 17 Phase 2, 10 Phase 3, 6 Phase 4, 5 Phase 1, 2 Not applicable.
Follow nabilone: new trials by email Literature Review of nabilone trials Research Report on nabilone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder PP-01, Nabilone, Placebo - Cannabis Withdrawal | Phase 3 | Recruiting | PleoPharma, Inc. | 420 | 2026-06-17 | 2026-10-27 |
| Nabilone Use For Acute Pain in Inflammatory Bowel Disease Patients Nabilone, Placebos - Inflammatory Bowel Diseases | Not applicable | Unknown | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | 80 | 2023-12-01 | 2023-06-07 |
| Investigating the Effects of Nabilone on Endocannabinoid Metabolism Nabilone Oral Capsule - Healthy | Phase 4 | Completed | Centre for Addiction and Mental Health | 10 | 2023-10-31 | 2026-03-11 |
| Nabilone for Agitation in Frontotemporal Dementia Nabilone, Placebo - Frontotemporal Dementia, Frontotemporal Dementia, Behavioral Variant | Phase 2 | Terminated | Simon Ducharme, MD | 3 | 2023-03-07 | 2026-07-28 |
| Cannabinoids and an Anti-inflammatory Diet for the Treatment of Neuropathic Pain After Spinal Cord Injury Placebo diet, Anti-inflammatory diet, Nabilone Capsules - Spinal Cord Injuries, Neuropathic Pain | Phase 3 | Completed | Eldon Loh, MD | 14 | 2023-03-01 | 2025-07-22 |
| Effect of PP-01 on Cannabis Withdrawal Syndrome PP-01 High Dose, PP-01 Low Dose, Placebo - Cannabis Withdrawal | Phase 2 | Completed | PleoPharma, Inc. | 234 | 2022-10-27 | 2024-08-16 |
| DIalysis Symptom COntrol-Pruritus Outcome Trial Nabilone 0.5 MG Oral Capsule, Placebo Nabilone - End Stage Renal Disease, Pruritus | Phase 3 | Completed | University of Manitoba | 14 | 2022-08-02 | 2023-11-30 |
| Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities Nabilone - Intellectual Disability, Developmental Disability | Phase 1 | Completed | Hsiang-Yuan Lin | 20 | 2022-03-17 | 2026-01-23 |
| Multimodal Assessment of Cannabinoid Target Engagement in Adults With Obsessive-Compulsive Disorder Nabilone, Placebo - Obsessive-Compulsive Disorder | Phase 1 / Phase 2 | Withdrawn | New York State Psychiatric Institute | 2022-03-01 | 2024-05-21 | |
| A Pilot Trial of Nabilone for the Treatment of Obesity Placebo, Nabilone - Obesity | Phase 2 | Terminated | Centre for Addiction and Mental Health | 18 | 2021-09-17 | 2026-04-09 |
| Adjunctive CB1 Agonist Nabilone in Inpatients With Active Suicidal Ideation Nabilone, Placebo - Suicidal Ideation | Phase 2 | Withdrawn | The University of Texas Health Science Center, Houston | 2021-04-01 | 2021-09-22 | |
| Nabilone for Agitation Blinded Intervention Trial Nabilone, Placebo - Alzheimer Disease, Agitation | Phase 3 | Recruiting | Sunnybrook Health Sciences Centre | 112 | 2021-02-01 | 2026-11-06 |
| Nabilone for Non-motor Symptoms in Parkinson's Disease Nabilone 0.25 mg - Parkinson Disease | Phase 3 | Completed | Medical University Innsbruck | 22 | 2018-08-06 | 2021-03-02 |
| Nabilone for Non-motor Symptoms in Parkinson's Disease Nabilone 0.25 mg, Placebo - Parkinson Disease | Phase 2 | Completed | Medical University Innsbruck | 48 | 2017-10-03 | 2021-03-02 |
| Cannabinoid Medication for Adults With OCD Nabilone, Exposure and Response Prevention Therapy - Obsessive-Compulsive Disorder | Phase 1 / Phase 2 | Completed | New York State Psychiatric Institute | 16 | 2016-09-01 | 2020-08-06 |
| Nabilone in Cannabis Users With PTSD Nabilone, Cannabis, Propranolol - Cannabis, Post Traumatic Stress Disorder | Phase 1 / Phase 2 | Terminated | New York State Psychiatric Institute | 4 | 2015-10-01 | 2022-07-15 |
| Safety and Efficacy of Nabilone in Alzheimer's Disease Nabilone, Placebo - Alzheimer Disease, Agitation | Phase 2 / Phase 3 | Completed | Sunnybrook Health Sciences Centre | 38 | 2015-01-01 | 2020-06-25 |
| Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Lung Cancer Patients Nabilone, Placebo - Non-Small Cell Lung Cancer, Anorexia | Phase 2 / Phase 3 | Unknown | Instituto Nacional de Cancerologia de Mexico | 78 | 2014-12-01 | 2016-08-31 |
| Nabilone and THC/CBD for the Treatment of FBSS Refractory Pain Nabilone, THC/CBD - FBSS | Completed | Azienda Ospedaliera Universitaria Policlinico "G. Martino" | 20 | 2014-09-01 | 2019-01-16 | |
| Study of Prevention of Postoperative Nausea and Vomiting Using Cesamet Nabilone, Placebo - Postoperative Nausea and Vomiting | Phase 2 | Completed | Unity Health Toronto | 331 | 2014-04-01 | 2015-12-03 |
Showing 20 of 34. Sign in to see all of them.
Pain (5) · Marijuana Abuse (4) · Neuralgia (4) · Psychomotor Agitation (3) · Alzheimer Disease (2) · Diabetic Neuropathies (2) · Fibromyalgia (2) · Multiple Sclerosis (2) · Obsessive-Compulsive Disorder (2) · Parkinson Disease (2) · Sleep Initiation and Maintenance Disorders (2) · Spinal Cord Injuries (2) · Aggression (1) · Anorexia (1) · Aphasia, Primary Progressive (1)
University of Manitoba (4) · NEMA Research, Inc. (3) · New York State Psychiatric Institute (3) · Centre for Addiction and Mental Health (2) · Medical University Innsbruck (2) · PleoPharma, Inc. (2) · Sunnybrook Health Sciences Centre (2) · Azienda Ospedaliera Universitaria Policlinico "G. Martino" (1) · Eldon Loh, MD (1) · Hsiang-Yuan Lin (1) · Instituto Nacional de Cancerologia de Mexico (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Mclean Hospital (1) · National Institute on Aging (NIA) (1) · Samuel Lunenfeld Research Institute, Mount Sinai Hospital (1)
Canada (18) · United States (12) · Austria (2) · Mexico (1)
Joseph V Pergolizzi, MD (3) · Charlotte A Richmond, PhD (2) · Jay Constantine, MD (2) · Aaron P Hong, MD, FRCPC (1) · Bernard Le Foll, MD, PhD (1) · Charlotte Richmond, PhD (1) · Chee W Chia, M.D. (1) · Colin M. Shapiro, MBBCh, PhD (1) · Cory Toth, MD (1) · David Collister, MD, PhD (1) · David Ditor, MD (1) · Domenico Quattrone, MD (1) · Eldon Loh, MD (1) · Giovanni Marotta, MD (1) · Helen B Simpson, M.D., Ph.D. (1)
PMID 11726775, PMID 11786587, PMID 12457271, PMID 14581124, PMID 14622184, PMID 15778874, PMID 15857739, PMID 16376734, PMID 16408219, PMID 16563625, PMID 16645457, PMID 1666930, PMID 16849753, PMID 16873343, PMID 17589370, PMID 17603035, PMID 18402303, PMID 18574361, PMID 20117132, PMID 21343383, PMID 21471961, PMID 21795981, PMID 21910367, PMID 22048225, PMID 22095142, PMID 22119709, PMID 22917662, PMID 22921260, PMID 23648372, PMID 25288189, PMID 26103030, PMID 28160217, PMID 29550881, PMID 30753761, PMID 31182351, PMID 31322567, PMID 31547752, PMID 32757413, PMID 34532852, PMID 35937495, PMID 3774823, PMID 40353878, PMID 7028791, PMID 8035251, PMID 8558188
K23MH125315 (1), K99DA029115 (1), U01DA066079 (1), U54DA037842 (1)